FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with compound which contains a) first component, able to bind with receptors of cells ER+ and b) second component, where first component is selective modulator of estrogen receptor (SERM), and where second component represents toxin, inactivating ribosomes, and is conjugated with first component, as well as deals with pharmaceutical composition, compound application, method of obtaining and method of cancer treatment.
EFFECT: group of invention ensures reduction of tumour without toxic side effects of medication action.
28 cl, 6 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PROPHYLAXIS AND TREATMENT OF ESTROGEN-DEPENDENT DISEASES AND DISORDERS | 1998 |
|
RU2214236C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
| COMPLEX THERAPY FOR CANCER TREATMENT | 2018 |
|
RU2810487C2 |
| VECTOR POLYPEPTIDE ANALOG OF TRANSFORMING GROWTH FACTOR ALPHA (TGF) FRAGMENT, ITS ANTITUMOR CONJUGATE AND PHARMACEUTICAL COMPOSITION ON CONJUGATE BASE | 2004 |
|
RU2277930C1 |
| CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (FOR INSTANCE, SERMS OR ALKYLATING AGENTS) | 2009 |
|
RU2543034C2 |
| HUMAN ANTIBODIES AND CONJUGATES OF ANTIBODY-PREPARATION AGAINST CD74 | 2012 |
|
RU2636029C2 |
| CONJUGATE POSSESSING SELECTIVE EFFECT WITH RESPECT TO CANCER TUMORS | 2005 |
|
RU2303997C2 |
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| CANCER-MODIFYING ANTIBODIES | 2008 |
|
RU2468036C2 |
